全文获取类型
收费全文 | 348421篇 |
免费 | 17426篇 |
国内免费 | 9993篇 |
专业分类
耳鼻咽喉 | 2794篇 |
儿科学 | 8898篇 |
妇产科学 | 6322篇 |
基础医学 | 34460篇 |
口腔科学 | 4940篇 |
临床医学 | 34323篇 |
内科学 | 56376篇 |
皮肤病学 | 2599篇 |
神经病学 | 24865篇 |
特种医学 | 14931篇 |
外国民族医学 | 59篇 |
外科学 | 46968篇 |
综合类 | 31534篇 |
现状与发展 | 26篇 |
一般理论 | 24篇 |
预防医学 | 30688篇 |
眼科学 | 7522篇 |
药学 | 28074篇 |
172篇 | |
中国医学 | 10557篇 |
肿瘤学 | 29708篇 |
出版年
2024年 | 522篇 |
2023年 | 2339篇 |
2022年 | 5512篇 |
2021年 | 8181篇 |
2020年 | 6227篇 |
2019年 | 5342篇 |
2018年 | 27201篇 |
2017年 | 22357篇 |
2016年 | 24095篇 |
2015年 | 8516篇 |
2014年 | 10523篇 |
2013年 | 10586篇 |
2012年 | 21335篇 |
2011年 | 36022篇 |
2010年 | 29194篇 |
2009年 | 20048篇 |
2008年 | 29820篇 |
2007年 | 31843篇 |
2006年 | 10322篇 |
2005年 | 11034篇 |
2004年 | 9556篇 |
2003年 | 9925篇 |
2002年 | 7082篇 |
2001年 | 4174篇 |
2000年 | 3949篇 |
1999年 | 3527篇 |
1998年 | 1924篇 |
1997年 | 1819篇 |
1996年 | 1416篇 |
1995年 | 1326篇 |
1994年 | 1234篇 |
1993年 | 708篇 |
1992年 | 1090篇 |
1991年 | 1024篇 |
1990年 | 927篇 |
1989年 | 753篇 |
1988年 | 680篇 |
1987年 | 567篇 |
1986年 | 455篇 |
1985年 | 372篇 |
1984年 | 251篇 |
1983年 | 218篇 |
1982年 | 135篇 |
1981年 | 107篇 |
1980年 | 120篇 |
1979年 | 157篇 |
1978年 | 135篇 |
1977年 | 91篇 |
1974年 | 122篇 |
1972年 | 94篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Valerie Iles 《Health care analysis》2016,24(2):105-118
This paper takes a somewhat slant perspective on flourishing and care in the context of suffering, death and dying, arguing that care in this context consists principally of ‘acts of work and courage that enable flourishing’. Starting with the perception that individuals, society and health care professionals have become dulled to death and the process of dying in Western advanced health systems, it suggests that for flourishing to occur, both of these aspects of life need to be faced more directly. The last days of life need to be ‘undulled’. Reflections upon the experiences of the author as carer and daughter in the face of her mother’s experience of death are used as basis for making suggestions about how care systems and professionals might better assist people in dealing with ‘the most grown up thing’ humans ever do, which is to die. 相似文献
42.
43.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
44.
45.
46.
M. Alexandra Friedman Charlotte M. Niznik Janelle R. Bolden Lynn M. Yee 《Journal of community health》2016,41(2):354-358
While peer support has been investigated in multiple clinical contexts, its application to the postpartum setting is unknown. The aim was to assess acceptability of a postpartum peer support program for women with diabetes. Observational survey-based needs assessment of forty low-income women with diabetes, receiving care at a major medical institution. Mean age and gravidity were 30.7 years and 3.15 ± 1.67 respectively. 45 % expressed interest in a “buddy.” There was no significant difference between groups desiring and not desiring this program. A majority of respondents desired telephone, text messaging, and in-person contacts (79.2, 72.1, 83.8 %), with 72.5 % of patients desiring diabetes-related activities during clinic waiting time. Many women desire a postpartum diabetes reciprocal peer program for support outside of clinician visits. Patients are receptive to educational services during their wait and outside of clinic time, a potentially valuable opportunity to share important health information. 相似文献
47.
48.
肠易激综合征(IBS)是一种常见的功能性疾病,中医病名为"肠郁"。郭朋教授根据IBS生理、病理特点,以疏肝健脾法调和肝脾,辨证施治,取得良好疗效。文章从病因病机、辨证论治及经典案例介绍等几个方面对郭教授治疗IBS经验进行系统阐述,以期为中医药治疗IBS提供理论和方法学参考。 相似文献
49.
50.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献